Original articleEfficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE)
Key words
Abbreviations used
Cited by (0)
Drs Simpson and Flohr contributed to this manuscript equally.
Funding sources: Funded by Genentech, a member of the Roche Group. Editorial assistance was provided by Wemimo Omotosho, PhD, of MediTech Media, funded by Genentech. Dr Flohr is funded through a National Institute for Health Research (NIHR) Career Development Fellowship (CDF-2014-07-037), and also supported by the NIHR Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College London.
Conflicts of interest: Dr Simpson reports grants, personal fees, and nonfinancial support from Roche-Genentech during the conduct of the study; personal fees from AbbVie, Celgene, Dermira, Galderma, LEO Pharma, Menlo Therapeutics, Sanofi Genzyme, and Valeant Pharmaceutical; grants and personal fees from Anacor Pharma, GlaxoSmithKline, and Regeneron Pharmaceuticals; grants from MedImmune, Novartis, Roivant Sciences, Tioga Pharmaceuticals, and Vanda Pharmaceuticals; and grants and personal fees from Eli Lilly outside the submitted work. Dr Flohr reports personal fees from Sanofi Regeneron outside the submitted work. The views expressed are those of the author(s), and not necessarily those of the UK NIHR or the UK Department of Health. Dr Eichenfield reports personal fees and nonfinancial support from Roche-Genentech during the conduction of the study and the following activities: Sanofi Regeneron (investigator, consultant, speaker); Cutanea (consultant); Dermavant (investigator); Eli Lilly (consultant); Galderma (investigator, consultant); Anacor/Pfizer (investigator, consultant); Novartis (consultant); LEO (investigator, consultant); Medimetriks (consultant); and Valeant (investigator, consultant). Dr Bieber has the following declaration of interests: Roche (consultant); Sanofi Regeneron (investigator, consultant, speaker); Eli Lilly (investigator, consultant, speaker); Galderma (investigator, consultant); Pfizer (investigator, consultant); Novartis (investigator, consultant); GlaxoSmithKline (consultant, speaker); LEO (investigator, consultant, speaker); and AbbVie (consultant). Dr Sofen reports personal fees from Genentech during the conduction of the study and personal fees from Regeneron and LEO outside the submitted work. Dr Taïeb has nothing to disclose. Drs Owen, Putnam, DeBusk, Lin, and Omachi are employees of Genentech, a member of the Roche group, and have a patent pending. Dr Yen is an employee of Roche and has a patent pending. Dr Voulgari is an employee of Roche Products Ltd.
Previously presented: Data from this study were presented at the European Academy of Dermatology and Venereology in Vienna, Austria on October 1, 2016.
Reprints not available from the authors.